The key findings were: Tirzepatide met the primary goal of cardiovascular non-inferiority , confirming it is at least as safe for the heart as dulaglutide It did not quite meet statistical superiority over dulaglutide for MACE, although results trended in favour of tirzepatide Tirzepatide produced significantly greater reductions in HbA1c and body weight than dulaglutide Importantly, because SURPASS-CVOT used an active comparator with established cardiovascular benefit rather than a placebo, demonstrating superiority was inherently more difficult than in earlier placebo-controlled GLP-1 outcome trials
IGF-1 LR3 Receptor Grade (Peptide) is manufactured under controlled laboratory conditions with strict quality assurance protocols
Using a phospholipid shell, it mimics the delivery method of our glutathione, allowing both nutrients to work together without being degraded by stomach acid
Abdullah M, Jamil RT, FN A
38 ChiranjeeviG.MuthukumaranM.KrishnamoorthyB
Retatrutide, like other incretin-based agents, produces weight loss that includes a proportion of lean body mass alongside fat tissue, as observed with GLP-1 receptor agonist class data